Humana Inc vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Humana Inc trades at $427.5 (market cap $50.48B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $38.01 (market cap $63.57B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is the larger of the two by market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| HUM | RELX | |
|---|---|---|
Market Cap | $50.48B | $63.57B |
Volume | 1,889,709 | 1,602,093 |
Sector | Health | Industrials |
52-Week High | $433.50 | $46.80 |
52-Week Low | $163.67 | $27.73 |
Typical Hold Time | 51 Days | — |
Enterprise Value | $57.83B | $75.05B |
Dividend Yield | 0.84% | 2.49% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $427.59, down 1.36% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is robust, reaching $129.66 billion in 2025, though net income margins have compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and strong institutional buying interest, while the company prepares for Q3 earnings on November 6.
The stock offers upside to the $469.89 consensus target but faces risks from margin pressure and regulatory scrutiny. Earnings beats in recent quarters support momentum, yet profitability trends and Medicare Advantage plan changes require monitoring for sustained growth.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Trailing returns across standard periods
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →